Earnings Releases·Oct 29, 2026, 7:01 AM ET

Insmed — Third Quarter 2026 Earnings Summary

Total Q3 2026 revenue surged 268% year-over-year to $524.4 million, driven by BRINSUPRI ($400.1 million, +29% QoQ) and ARIKAYCE ($124.4 million, +9% YoY); net loss narrowed to $100.3 million from $370.0 million in the prior year period.
Full-year 2026 revenue guidance was raised for both BRINSUPRI ($1.35B–$1.4B) and ARIKAYCE ($460M–$470M), with management projecting peak revenues exceeding $7B for BRINSUPRI, $6B for TPIP, and $1B for ARIKAYCE.
Key regulatory and commercial milestones include the FDA's acceptance of the sNDA for ARIKAYCE with Priority Review (target action date Jan 28, 2027), the launch of BRINSUPRI Tablets in Japan, and the initiation of Phase 3 studies for TPIP in IPF (H1 2027) and PALM-PAH.
The company appointed Paul Hudson and Utpal Koppikar to its Board of Directors and maintains a strong liquidity position with $1.1 billion in cash and marketable securities as of September 30, 2026.